| 尹晓明,孙云川,胡婷婷,何新颖,毕建强,肖丽,黄如敬,鲁洪岭,王俊杰.192Ir高剂量率近距离放疗在结直肠癌术后复发肺内寡转移治疗的初步应用[J].中华放射医学与防护杂志,2019,39(11):833-836 |
| 192Ir高剂量率近距离放疗在结直肠癌术后复发肺内寡转移治疗的初步应用 |
| Preliminary application of 192Ir high-dose rate brachytherapy in postoperative recurrent colorectal cancer with intrapulmonary oligometastases |
| 投稿时间：2019-03-26 |
| DOI：10.3760/cma.j.issn.0254-5098.2019.11.006 |
| 中文关键词: 结直肠癌 肺转移 高剂量率近距离放疗 192Ir |
| 英文关键词:Colorectal cancer Lung metastasis High dose ratebrachytherapy 192Ir |
| 基金项目: |
|
| 摘要点击次数: 2264 |
| 全文下载次数: 1226 |
| 中文摘要: |
| 目的 初步探讨运用近距离放射治疗结直肠癌术后复发肺内寡转移患者的临床疗效，评估其可行性。方法 回顾性收集河北省沧州中西医结合医院自2013年5月至2017年10月入院的结直肠癌术后肺内寡转移患者的病例，10例患者共15个病灶，采用CT引导下192Ir高剂量率近距离放射治疗肺部转移病灶。应用定位CT扫描图像，将插植针置入肿瘤，在CT引导下调整插植针至合适位置，将插植完成后图像传至计划系统，勾画靶区和危及器官，进行三维重建，制定放疗计划，计划通过后实施治疗，采用单次放疗，剂量20 Gy。结果 10例患者均顺利完成治疗，1级不良事件发生率30%，其中1例为轻度咳嗽，2例为痰中带血，无严重不良事件发生。治疗后1年肿瘤局部控制率（LC）为93.3%，其中1例患者治疗6个月后局部进展，再次实施近距离放射治疗，中位无进展生存期（PFS）为8.5个月，中位总生存（OS）为14.7个月。结论 对于无法手术的结直肠癌术后复发肺内寡转移患者来说，近距离放射治疗是一种可选择的安全可行的治疗方式，短期内可重复治疗，不良反应小，肿瘤局部控制率佳。 |
| 英文摘要: |
| Objective To investigate the efficacy and feasibility of 192Ir high-dose rate brachytherapy for recurrent intrapulmonary oligometastasis after colorectal cancer surgery. Methods Patients from May 2013 to October 2017 with intrapulmonary oligometastasisafter colorectal cancer surgery in Cangzhou Integrated Traditional Chinese and Western Medicine Hospital were enrolled. A total of 15 lesions were obtained from 10 patients, which were treated with CT-guided high dose rate of 192Ir. The implant needles were inserted into the tumor and were adjusted to appropriate positions under the guidance of CT. Then the images after transplanting were uploaded to the planning system to delineate the target area and the organ at risk volume. Patients underwent a single radiation dose of 20 Gy. Results All 10 patients were successfully treated. Grade 1 adverse events were observed for 30% of patients. Of the 10 patients, one patient had a mild cough, and two had bloody sputum. There was no serious adverse events occurred. The local control rate (LC) of the patients at 1 year after treatment was achieved in 93.3%. Only one developed local advancement after six months, who received the secondary brachytherapy. The median progression-free survival(PFS) was 8.5 months and the median overall survival(OS) was 14.7 months. Conclusions High dose rate brachytherapy is effective in terms of recurrent lung metastases after surgery for colorectal cancer, with a moderate rate of adverse reactions and a favorable local tumor control rate. |
| HTML 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |